Health2Sync announced that its latest version of the Health2Sync App integrates insulin data from Mallya® Cap, the connected device dedicated to insulin pens developed by Biocorp and marketed in Japan by Novo Nordisk. This partnership realizes the first data integration of its kind in the world and is expected to help patients on insulin treatment manage their health by capturing multiple data points, including insulin injection logs. The population of diabetes and pre-diabetes exceeds 20 million in Japan.

Health2Sync plans to deploy comprehensive digital insulin management experiences to other countries this year.